ATE389415T1 - Verfahren und mittel zur erhöhung der darmabsorption - Google Patents

Verfahren und mittel zur erhöhung der darmabsorption

Info

Publication number
ATE389415T1
ATE389415T1 AT03760706T AT03760706T ATE389415T1 AT E389415 T1 ATE389415 T1 AT E389415T1 AT 03760706 T AT03760706 T AT 03760706T AT 03760706 T AT03760706 T AT 03760706T AT E389415 T1 ATE389415 T1 AT E389415T1
Authority
AT
Austria
Prior art keywords
increase intestinal
egf
intestinal absorption
relates
producing
Prior art date
Application number
AT03760706T
Other languages
English (en)
Inventor
Lothar Steidler
Original Assignee
Actogenix Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actogenix Nv filed Critical Actogenix Nv
Application granted granted Critical
Publication of ATE389415T1 publication Critical patent/ATE389415T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Radio Relay Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03760706T 2002-06-19 2003-06-19 Verfahren und mittel zur erhöhung der darmabsorption ATE389415T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02077532 2002-06-19

Publications (1)

Publication Number Publication Date
ATE389415T1 true ATE389415T1 (de) 2008-04-15

Family

ID=29797233

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03760706T ATE389415T1 (de) 2002-06-19 2003-06-19 Verfahren und mittel zur erhöhung der darmabsorption

Country Status (9)

Country Link
US (1) US7601799B2 (de)
EP (1) EP1513545B1 (de)
JP (1) JP2005529622A (de)
AT (1) ATE389415T1 (de)
AU (1) AU2003250250B2 (de)
CA (1) CA2489930A1 (de)
DE (1) DE60319822T2 (de)
ES (1) ES2302945T3 (de)
WO (1) WO2004001020A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60319822T2 (de) 2002-06-19 2009-06-04 Actogenix Nv Verfahren und mittel zur erhöhung der darmabsorption
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
JP2012504116A (ja) * 2008-09-29 2012-02-16 アクトジェニックス・エヌブイ 粘膜での微生物のコロニー形成の低減
KR101667982B1 (ko) * 2010-01-14 2016-10-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 염증성 장 질환(ibd) 및 과민성 장 증후군(ibs)의 예방 및 치료를 위한 재조합 프로바이오틱 박테리아
EP2830599B1 (de) 2012-03-29 2018-08-15 Therabiome, Llc Ortsspezifische gastrointestinale orale impfrezepte zur wirkung am ileum und am blinddarm
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN103710351B (zh) * 2013-12-23 2015-12-09 江苏众红生物工程创药研究院有限公司 表皮生长因子重组乳酸菌及其应用
CN107325998A (zh) * 2017-06-20 2017-11-07 江西嘉博生物工程有限公司 一种表达猪表皮生长因子基因的重组乳酸乳球菌及构建方法
JP7316802B2 (ja) * 2019-02-19 2023-07-28 雪印メグミルク株式会社 糖吸収促進用組成物
IT201900014550A1 (it) * 2019-08-09 2021-02-09 Abiogen Pharma Spa Uso di colecalciferolo come agente attivo nel trattamento della celiachia
CN116676246A (zh) * 2023-06-16 2023-09-01 华中农业大学 重组乳酸乳球菌、益生菌制剂、构建方法、cECF表达方法及应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100495A (en) 1975-11-27 1978-07-11 Cselt - Centro Studi E Laboratori Telecomunicazioni Adaptive method of and means for recovering digital signals
US4190495A (en) 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4874702A (en) 1980-09-08 1989-10-17 Biogen, Inc. Vectors and methods for making such vectors and for expressive cloned genes
US4888170A (en) 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
DE3578852D1 (de) 1984-09-26 1990-08-30 Lilly Co Eli Verfahren zur expression und sekretion in bacillus.
US5032510A (en) 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
WO1988006626A1 (en) 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5591632A (en) 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5330753A (en) 1987-04-29 1994-07-19 President And Fellows Of Harvard College Cholera vaccines
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
IE892131A1 (en) 1989-06-30 1991-01-02 Univ Cork Marker genes for genetic manipulation
US5149532A (en) 1989-11-01 1992-09-22 Cedars Sinai Medical Center Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
DE4006521A1 (de) 1990-03-02 1991-09-05 Bayer Ag Zuckerhaltige polymere zur umhuellung und einbettung von arzneistoffen
GB9006400D0 (en) 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
IL99097A0 (en) 1990-09-05 1992-07-15 Akzo Nv Haemophilus paragallinarum vaccine
SK55593A3 (en) 1991-03-05 1993-10-06 Wellcome Found Expresion of recombinant proteins in attenuated bacteria
EP0607278B1 (de) 1991-10-07 2002-04-17 The Brigham And Women's Hospital, Inc. Verfahren zur erhöhung der darmabsorption
IL103530A0 (en) 1991-10-25 1993-03-15 Duphar Int Res Treponema hyodysenteriae vaccine
EP0628083A1 (de) 1992-02-27 1994-12-14 Microbial Technics Limited Heterologe genexpression in lactococcus und die entsprechenden expressionsprodukte
US5455034A (en) 1992-06-26 1995-10-03 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
DE4231764A1 (de) 1992-09-23 1994-03-24 Inst Pflanzengenetik & Kultur Verfahren zur chromosomalen Integration eines Produkt-Gens
US5691185A (en) 1993-10-08 1997-11-25 Chr. Hansen A/S Lactic acid bacterial suppressor mutants and their use as selective markers and as means of containment in lactic acid bacteria
CA2173751A1 (en) 1993-10-13 1995-04-20 Sýren Molin Recombinant staphylococcal nucleases and their use in limiting the survival of genetically engineered microorganisms
IT1270123B (it) * 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
US5753622A (en) 1995-05-10 1998-05-19 University Technologies International, Inc. Use of epidermal growth factor as a gastrointestinal therapeutic agent
ATE312934T1 (de) 1995-06-07 2005-12-15 Univ Washington Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
GB9518323D0 (en) 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
JP2000510332A (ja) 1996-04-19 2000-08-15 ヘンリー エム.ジャクソン ファンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン インチミンを単独で、または1以上の他の抗原との融合タンパク質として発現する宿主生物の投与による、免疫応答を刺激する方法
US5972887A (en) 1996-09-19 1999-10-26 The Nemours Foundation Treatment of intestinal epithelial cell malfunctions with Hepatocyte Growth Factor
GB9700939D0 (en) 1997-01-17 1997-03-05 Microbial Technics Limited Therapy
DE69942249D1 (de) 1998-05-07 2010-05-27 Univ Bruxelles Auf cytotoxinen basierendes biologisches einschlusssystem
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
WO2000001799A2 (en) 1998-07-03 2000-01-13 Chr. Hansen A/S Method of preventing bacteriophage infection of bacterial cultures
WO2000018377A1 (en) 1998-09-28 2000-04-06 Warner-Lambert Company Enteric and colonic delivery using hpmc capsules
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
EP1123314B1 (de) * 1998-10-20 2004-02-18 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
CA2446776C (en) 2001-05-03 2011-07-12 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Self-containing lactococcus strain
EP1319410A1 (de) * 2001-12-11 2003-06-18 Société des Produits Nestlé S.A. Verwendung von Mikroorganismen zur gezielten Verabreichung von Mitteln in specifischen Teilen des Darms
US20040043003A1 (en) 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
DE60319822T2 (de) 2002-06-19 2009-06-04 Actogenix Nv Verfahren und mittel zur erhöhung der darmabsorption
AU2003298291A1 (en) 2002-11-15 2004-06-15 Universiteit Gent Self-containing lactobacillus strain

Also Published As

Publication number Publication date
AU2003250250B2 (en) 2008-02-14
EP1513545A2 (de) 2005-03-16
US7601799B2 (en) 2009-10-13
AU2003250250A1 (en) 2004-01-06
WO2004001020A2 (en) 2003-12-31
DE60319822T2 (de) 2009-06-04
JP2005529622A (ja) 2005-10-06
WO2004001020A3 (en) 2004-03-04
CA2489930A1 (en) 2003-12-31
ES2302945T3 (es) 2008-08-01
US20050158282A1 (en) 2005-07-21
EP1513545B1 (de) 2008-03-19
DE60319822D1 (de) 2008-04-30

Similar Documents

Publication Publication Date Title
DE60319822D1 (de) Verfahren und mittel zur erhöhung der darmabsorption
ATE421256T1 (de) Probiotische zusammensetzung
ATE489853T1 (de) Verbesserung des wachstums von bifidobakterien in fermentierten milchprodukten
WO2009043856A3 (en) Modulation of tissue fatty acid composition of a host by human gut bacteria
EP1567660A4 (de) MIT MILCHSûUREBAKTERIEN VERGORENERGINSENG, DIESEN ENTHALTENDER JOGHURT SOWIE ZUR HERSTELLUNG DAVON VERWENDETEMILCHSûUREBAKTERIEN
DE602004006133D1 (de) Neue galactooligosaccharidzusammensetzung und herstellung davon
ATE439138T1 (de) Probiotika zur primären prävention atopischer erkrankungen
ATE444074T1 (de) Antiallergisches mittel, seine verwendung zur verringerung von allergien und verfahren zur verringerung von allergien
EP1510570A3 (de) Verfahren zur Herstellung der L-Histidine durch die Verwendung von Bakterien aus der Familie Enterobacteriaceae
ATE454443T1 (de) Verfahren zur herstellung anallergischer probiotischer bakterienkulturen und entsprechende verwendung
DE60123986D1 (de) Verwendung eines mittels zur verbesserung des knochenmetabolismus
WO2008078387A1 (ja) 皮膚改善用及び/又は治療用の発酵乳とその製造方法
ATE480248T1 (de) Verwendung von milchsäurebakterien zur verringerung von zahnfleischbluten und mundentzündung
WO2003045405A3 (fr) Bacteries lactiques et leur usage dans le traitement et la prevention du cancer
ATE306821T1 (de) Pulver zum ansatz für eine probiotische joghurtspeise
MXPA04005346A (es) Uso de microorganismos para una distribucion dirigida de sustancias a partes especificas del intestino.
ATE451018T1 (de) Verfahren zur herstellung von sauermilchprodukten mit enzymen bakteriellen ursprungs
EP3752627A4 (de) Mikroorganismen und verfahren zur herstellung von milchsäure
DE602004023098D1 (de) Neues lactobacillus, den lebenden körper aktivierende lactobacilluspräparation sowie präventivmittel oder therapeutikum gegen eine infektion des lebenden körpers
ATE541468T1 (de) Mikrobielle futterergänzungsmittel und verwendungen davon in verfahren zur verringerung und/oder verhinderung von azidose in polygastrischen pflanzenfressern
WO2007015132A3 (en) Use of specific lactic bacteria for the preparation of immunomodulating compositions
BR0308227A (pt) Método para melhorar os procedimentos de fermentação de alimentos
ATE542887T1 (de) Neuartiger milchsäurebakterienstrang, fermentiertes nahrungsmittel/getränk und verfahren zur herstellung eines fermentierten nahrungsmittels/getränks
RU2010153265A (ru) Способ уменьшения урчания в животе путем введения бактерий рода bifidobacterium
DE50107566D1 (de) Nukleotidsequenzen kodierend fur proteine beteiligt an der biosynthese von l-serin, verbessertes verfahren zur mikrobiellen herstellung von l-serin sowie ein dazu geeigneter genetisch veranderter mikroorganismus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties